Analysis of long-term survivors after surgical resection for invasive pancreatic cancer
Corresponding Author
SHIGEHIRO KURE
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Shigehiro Kure, MD, Department of Surgery II, Graduate School of Medicine, University of Nagoya, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. Tel: +81 52 744 2249. Fax: +81 52 744 2255. E-mail: [email protected]Search for more papers by this authorTETSUYA KANEKO
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorSHIN TAKEDA
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorSOICHIRO INOUE
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorAKIMASA NAKAO
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorCorresponding Author
SHIGEHIRO KURE
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Shigehiro Kure, MD, Department of Surgery II, Graduate School of Medicine, University of Nagoya, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. Tel: +81 52 744 2249. Fax: +81 52 744 2255. E-mail: [email protected]Search for more papers by this authorTETSUYA KANEKO
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorSHIN TAKEDA
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorSOICHIRO INOUE
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorAKIMASA NAKAO
Department of Surgery II, Graduate School of Medicine, University of Nagoya, Japan
Search for more papers by this authorAbstract
Pancreatic cancer remains a lethal disease. Although there are many reports on the survival rates of pancreatic cancer patients after surgical resection, the clinicopathological characteristics that influence long-term survival over 5 years remain controversial. Here, we clarify the favourable prognostic factors for long-term survival. One hundred and eighty-two patients with pancreatic cancer underwent surgical resections from 1981 to 1997 in our department. Among them, eight patients survived for at least 5 years after the surgery. The clinicopathological characteristics of the eight long-term survivors who underwent radical resections were studied retrospectively. R0 surgical resections, including five combined with portal vein resections (62.5%), were achieved in these eight patients. Negative invasions of the major regional artery (seven of eight, 87.5%) and to the extrapancreatic nerve plexus (seven of eight, 87.5%), and N0 or N1 lymph node metastasis (7 of 8, 87.5%) were detected as clinicopathological features of long-term survivors in our study. No exposure of carcinoma at the dissected surface and cut end (seven of eight, 87.5%) was characteristically confirmed by pathology. Portal vein invasion was seen in three of the eight patients (37.5%). For long-term survival in cases of pancreatic cancer, complete R0 resections should be performed and negative invasions in the major regional arteries and to the extrapancreatic plexus of the nerve were necessary. No invasion to the portal vein was not necessarily required if R0 was achieved by combined resection of the portal vein.
References
- [1] Kaneko T, Kimata H, Sugimoto H, Inoue S, Ito S, Ishiguchi T, et al. Power doppler ultrasonography for the assessment of vascular invasion by pancreatic cancer. Pancreatology 2002; 2: 61–8.
- [2] Tezel E, Kaneko T, Sugimoto H, Takeda S, Inoue S, Nagasaka T, et al. Clinical significance of intraportal endovascular ultrasonography for the diagnosis of extrapancreatic nerve plexus invasion by pancreatic carcinoma. Pancreatology 2004; 4: 76–81.
- [3] Kaneko T, Nakao A, Inoue S, Harada A, Nonami T, Itoh S, et al. Intraportal endovascular ultrasonography in the diagnosis of portal vein invasion by pancreatobiliary carcinoma. Ann Surg 1995; 222: 711–18.
- [4] Lygidakis NJ, Papadopoulou P. Pancreatic head carcinoma: is pancreatic resection indicated for patients with stage III pancreatic duct cancer. Hepatogastroenterology 1995; 42: 587–96.
- [5] Nakao A, Nonami T, Harada A, Kasuga T, Takagi H. Portal vein resection with a new antithrombogenic catheter. Surgery 1990; 108: 913–18.
- [6] Nakao A, Takagi H. Isolated pancreatectomy for pancreatic head carcinoma using catheter bypass of the portal vein. Hepatogastroenterology 1993; 40: 426–9.
- [7] Nakao A, Harada A, Nonami T, Kaneko T, Inoue S, Takagi H. Clinical significance of portal invasion by pancreatic head carcinoma. Surgery 1995; 117: 50–5.
- [8] Ozaki H, Takehisa H, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999; 29: 16–22.
- [9] Nakao A, Harada A, Nonami T, Kaneko T, Murakami H, Inoue S, et al. Lymph node metastases in carcinoma of the head of the pancreas region. Br J Surg 1995; 82: 399–402.
- [10] Nakao A, Harada A, Nonami T, Kaneko T, Nomoto S, Koyama H, et al. Lymph node metastasis in carcinoma of the body and tail of the pancreas. Br J Surg 1997; 84: 1090–2.
- [11] Nakao A, Harada A, Nonami T, Kaneko T, Takagi H. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 1996; 12: 357–61.
- [12] Bakkevold KE, Kambestrad B. Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater – the prognostic factors influencing the long-term results. Eur J Surg Oncol 1993; 19: 147–61.
- [13] Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223: 147–53.
- [14] Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg 1996; 3: 273–9.
- [15] Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. Ann Surg 1995; 221: 721–33.
- [16] Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the west midlands: an epidemiological study. Br J Surg 1995; 82: 111–15.
- [17] Kedra B, Popiela T, Sierzega M, Precht A. Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterology 2001; 48: 1762–6.
- [18] Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001; 96: 2609–15.
- [19] Neoptolemos JP, Russell RCG, Bramhall S, Theis JB. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. Br J Surg 1997; 84: 1370–6.
- [20] Mannell A, Van Heerden JA, Weiland LH, Ilstrup DM. Factors influencing survival after resection for ductal adenocarcinoma of the pancreas. Ann Surg 1986; 203: 403–7.
- [21] Lerut JP, Gianello PR, Otte JB, Kestens PJ. Pancreaticoduodenal resection. Ann Surg 1984; 199: 432–7.
- [22] Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59–66.
- [23] Tsuchiya R, Oribe T, Noda T. Size of the tumor and other factors influencing prognosis of carcinoma of the head of the pancreas. Am J Gastroenterol 1985; 80: 459–62.
- [24] Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120–5.
- [25] Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68–73.
- [26] Yoshizawa K, Nagai H, Kurihara K, Sata N, Kawai T, Saito K. Long-term survival after surgical resection for pancreatic cancer. Hepatogastroenterology 2001; 48: 1153–6.
- [27] Nagakawa T, Ohta T, Kayahara M, Mori K, Ueda S, Kobayashi K, et al. Clinicopathological evaluation of long-term survivors treated for cancer of the head of pancreas. Hepatogastroenterology 1998; 45: 1865–9.
- [28] Nakao A, Kaneko T, Takeda S, Inoue S, Harada A, Nomoto S, et al. The role of extended radical operation for pancreatic cancer. Hepatogastroenterology 2001; 48: 949–52.
- [29] Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Ann Surg 1993; 217: 144–8.
- [30] Japan Pancreas Society Classification of pancreatic carcinoma, 2nd English edn. Kanehara & Co. Ltd: Tokyo ; 2003.
- [31] Johnstone PAS, Sindelar WF. Lymph node involvement and pancreatic resection: correlation with prognosis and local disease control in a clinical trial. Pancreas 1993; 8: 535–9.
- [32] Kaneko T, Nakao A, Inoue S, Nomoto S, Nagasaka T, Nakashima N, et al. Extrapancreatic nerve plexus invasion by carcinoma of the head of the pancreas. Diagnosis with intraportal endovascular ultrasonography. Int J Pancreatol 1996; 19: 1–7.
- [33] International Union Against Cancer (UICC)Sobin LH, Wittekind CH. TNM Classification of malignant tumours, 6th edn. Wiley: Chichester ; 2002.
- [34]
Nakao A,
Harada A,
Nonami T,
Kaneko T,
Inoue S,
Takagi H.
Intraoperative radiotherapy for resectable and unresectable pancreatic carcinoma.
J Hep Bil Pancr Surg
1994; 1: 252–6.
10.1007/BF02391076 Google Scholar
- [35] Takeda S, Inoue S, Kaneko T, Harada A, Nakao A. The role of adjuvant therapy for pancreatic cancer. Hepatogastroenterology 2001; 48: 953–6.
- [36] Nakao A, Harada A, Nonami T, Kaneko T, Takeda S, Kurokama T, et al. Intraoperative radiotherapy for pancreatic carcinoma with hepatic or peritoneal metastases. Hepatogastroenterology 1997; 44: 1469–71.
- [37] Dobelbower RR, Bronn DG. Radiotherapy in the treatment of pancreatic cancer. Baillieres Clin Gastroenterol 1990; 4: 969–83.